|
| |
|
Principal speakers: |
|
| |
Richard Begent |
Head, Cancer Research UK
Targeting and Imaging Group, UCL, UK |
| |
Carl Borrebaeck |
Head of Dept of Immunotechnology, Lund University, Sweden |
| |
Stefan Duebel |
Director, Technical
University of Braunschweig, Germany |
| |
Markus Enzelberger |
MorphoSys AG, Germany |
| |
Jim Huston |
Chairman, The Antibody
Society, USA |
| |
Kevin Johnson |
Chief Executive Officer, PanGenetics BV, Cambridge, UK |
| |
Robert Kamen |
Former President, Abbott
Bioresearch Center, USA |
| |
Bob Ladner |
Chief Technology Officer
and Senior Vice President, Dyax Corp, USA |
| |
Richard Lerner |
President, The Scripps
Research Institute, La Jolla, USA |
| |
Jim Marks |
Professor of Anesthesia
& Pharmaceutical Chemistry, University of California, San Francisco,
USA |
| |
John McCafferty |
Cell Interaction Group, Biochemistry Department, University of Cambridge, UK |
| |
Dario Neri |
Institute of
Pharmaceutical Sciences, ETH Zurich, Switzerland |
| |
Jane Osbourn |
Site Leader and VP Research, MedImmune, Cambridge, UK |
| |
Andreas Pluckthun |
Professor of
Biochemistry, University of Zurich, Switzerland |
| |
Dev Sidhu |
Associate Professor, CCBR, University of Toronto, Canada |
| |
Ian Tomlinson |
SVP, Biopharmaceuticals R&D, GlaxoSmithKline, UK |
| |
Tristan Vaughan |
Senior Director, Lead
Generation, Medimmune, UK |
| |
Trudi Veldman |
Director, Biologics
Generation, Abbott Bioresearch Center, USA |
| |
Diane Wilcock |
XOMA LLC, USA |
| |
Sir Gregory Winter
CBE FRS |
MRC Laboratory of Molecular Biology, Cambridge, UK |
Panellists |
|
| |
Debbie Allen |
Consultant, Andiamo
Biotech, UK |
| |
Andrew Bradbury |
Los Alamos National
Laboratories, USA |
| |
David Chiswell OBE |
Chief Executive Officer. Nabriva Therapeutics, Vienna,
Austria |
| |
Hennie Hoogenboom |
Consultant, The
Netherlands |
| |
Diane Mellett |
Chief Business Officer &
General Counsel, Affitech A/S, Norway |
| |
Thomas von Rueden |
Advisor, DIREVO Industrial Biotechnology GmbH, Germany |
| |
Supported by
|
